Entrada Therapeutics (TRDA) Liabilities and Shareholders Equity (2020 - 2026)

Entrada Therapeutics' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $335.5 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 31.03% year-over-year to $335.5 million; the TTM figure through Mar 2026 stood at $1.6 billion (down 26.74% YoY), while the FY2025 annual figure was $377.4 million, down 28.3% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $335.5 million, down from $377.4 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $582.0 million in Q2 2024, with the low at $252.1 million in Q4 2022.
• The 5-year median for Liabilities and Shareholders Equity is $469.2 million (2023), against an average of $429.3 million.
• The sharpest annual moves came in 2022 and 2026: Liabilities and Shareholders Equity jumped 107.31% in 2022, then tumbled 31.03% in 2026.
• Entrada Therapeutics' Liabilities and Shareholders Equity stood at $252.1 million in 2022, then jumped by 86.15% to $469.2 million in 2023, then gained by 12.18% to $526.3 million in 2024, then declined by 28.3% to $377.4 million in 2025, then decreased by 11.09% to $335.5 million in 2026.
• Business Quant data shows TRDA's Liabilities and Shareholders Equity at $335.5 million in Q1 2026, $377.4 million in Q4 2025, and $412.9 million in Q3 2025.